ALTASCIENCES
Altasciences , a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development from lead candidate selection to proof of concept, today announced that it has acquired Alliance Contract Pharma . This acquisition adds small molecule contract manufacturing and analytical services from API to commercialization, including commercial manufacturing, GMP warehouse storage, and clinical supply distribution, to Altasciences’ full-service preclinical, clinical, and bioanalytical offerings.
Transferring data, projects, and/or methodologies between CROs, or between different groups within a multi-service CRO, takes time, is prone to error, and can lead to prolonged R&D timelines. Altasciences is addressing these challenges through the integration of key strategic additions, such as their preclinical business in October 2018 , and now Alliance Contract Pharma. Clients partnering with Altasciences on their drug development programs benefit from working with a fully integrated CRO, allowing for quicker, more proactive development timeline adjustments and decision making to improve R&D efficiency.
“The addition of Alliance Contract Pharma continues to fulfill our strategy of creating a comprehensive offering that facilitates the outsourcing experience for our clients. We remain committed to providing our clients with value-added services that create a new paradigm of drug development outsourcing,” added Chris Perkin, CEO of Altasciences.
“We are excited to be joining a team that is responsive and understanding, and continuously looking to create innovative partnerships that redefine the status quo and address the challenges that our clients face in meeting critical milestones, ” stated Stephen Schweibenz, President of Alliance Contract Pharma.
BlackArch Partners served as exclusive financial advisor to Alliance Contract Pharma.
About Altasciences
Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005731/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
Illumynt Reports Q3 2025 Business Update17.10.2025 14:39:00 CEST | Press release
Q3 2025 was a busy quarter once again for us here at illumynt. In addition to naming a new CEO, we executed on a number of initiatives that are propelling our organization forward. Revenue for the quarter exceeded $30 million- keeping us on track for our 2025 plan. More importantly we executed three different large-scale data center decommission projects with almost no material ending up as scrap. All of the AI-focused enterprise equipment and components recovered from the decommissions were resold at top market value. We head into Q4 with high expectations and our eyes wide open. We’re celebrating the 20-year anniversary of our facility in Hong Kong and looking to add another location in the region to help us process inbound AI data center equipment. Stay tuned for updates. There will be more on the way. View source version on businesswire.com: https://www.businesswire.com/news/home/20251017446548/en/
Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 14:15:00 CEST | Press release
Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for t
Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents17.10.2025 13:00:00 CEST | Press release
AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom